ABOUT CYTIVA
With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery.
We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more.
PRODUCT VIDEOS
FEATURED PRODUCTS
-
The NanoAssemblr™ Ignite and Ignite+ systems provide an easy-to-use, scalable platform for reproducible lipid nanoparticle formulation. Choose the workflow and cartridge-use approach that fits your program today, with a validated path to clinical and commercial manufacturing when you are ready.
-
Learn how automating activation, transduction, and expansion in a closed workflow can simplify operations, reduce manual steps, and improve consistency while enabling real-time monitoring.
-
Explore how smart column design supports consistent, high‑yield oligonucleotide synthesis, which formats fit development, and how optimized features help improve efficiency and safety.
-
Gene therapies hold immense potential to provide long-lasting treatments for a wide range of diseases. At Cytiva, we offer GMP-compliant, end-to-end manufacturing solutions designed to support the development and commercialization of advanced medicines across multiple modalities – including AAV, adenovirus (AV), lentivirus (LV), plasmid DNA (pDNA) and exosomes. Our dependable suite of technologies and expertise ensures scalability, quality, and regulatory confidence at every stage of your journey.
-
Discover a medium that supports high-density HEK293 growth and robust AAV titers across scales for bioprocessing teams seeking consistency and scalability in viral vector manufacturing.
-
Platform of automated, single-use systems for tangential flow filtration at multiple scales.
-
Accelerate your gene therapy manufacturing with the Xcellerex™ X-platform – a next-generation single-use bioreactor system designed for viral vector workflows.
-
Optimize your cell line strategy for better viral vector production.
-
Whether you're looking to boost performance, enhance your capabilities, or simply get consistent, high-quality results, HyClone™ peak expression medium and HyClone™ prime expression medium are the solutions for you.
-
ÄKTA ready™ chromatography system 450 is a single-use liquid chromatography system.
-
The LevMixer™ 10 L single-use mixing system is a low volume mixer designed for both upstream and downstream applications.
-
The iCELLis™ bioreactor system is an automated, single-use, fixed-bed bioreactor that provides excellent cell growth conditions for adherent cells.
-
Gene therapy holds promise for treating genetic diseases, but the path from concept to product is complex. Learn how to navigate each step of the viral vector workflow with greater speed and confidence.
-
Examine a scalable, benchtop mixing system designed for sensitive fluids and GxP environments that supports automated control, traceability, and compliance from early development through production.
-
Explore media solutions for viral vector production that support HEK293 and insect cells, with custom development, analytical testing, and scalable preparation tools to optimize performance.
-
Support high transfection efficiency and viral titers in HEK293 cells with a chemically defined, hydrolysate-free formulation that enables seamless scale-up and shows improved viability over alternatives.
-
Support high-yield viral vector production with media designed for transfection efficiency, scalability, and reduced aggregation in HEK293 cells, ideal for AAV and LV workflows.
-
Discover a system with a flexible synthesis scale, intuitive software, and robust process control that is ideal for labs moving from research to production.
-
Research Use Only (RUO) lipid nanoparticle (LNP) reagents to deliver RNA into hematopoietic stem cells (HSCs) for cell and gene therapy applications.
-
Off-the-shelf, research use only lipid nanoparticle (LNP) reagents to deliver RNA into T-cells.
WEBINARS AND PODCASTS
APPLICATION NOTES
- Discover A System That Can Be Used With Various Cell Culture Media
- Developing CAR T Therapies With A Cell Therapy Manufacturing Platform
- Bring Greater Control To Your Cell Therapy Manufacturing
- Scalable rAAV9 Production Using Advanced Cell Lines And Bioreactors
- Scale-Up Of AAV Production In Fixed-Bed Bioreactors
- mRNA Manufacturing With Fed-Batch In Vitro Transcription
- Oligonucleotide Purification And Synthesis
- Cell Culture Media Mixing In A Benchtop Single-Use Mixer
- Assessing Particle Generation In A Single-Use Mixing System
- HyClone™ Prime Expression Medium
CONTACT INFORMATION
Cytiva
100 Results Way
Marlborough, MA 08855-1327
UNITED STATES
Phone: 800-526-3593
FEATURED ARTICLES
-
Optimizing LNPs for in vivo CAR-T requires aligning target selection, formulation design, and delivery performance to achieve functional CAR expression in desired T-cell populations while balancing specificity, safety, dosing flexibility, and manufacturability.
-
Choosing the right in vivo CAR-T manufacturing partner requires looking beyond cost to the capabilities that protect scalability, compliance, safety, and development timelines.
-
Moving mRNA-LNP production from lab to GMP scale exposes tensions among formulation consistency, regulatory expectations, and facility safety, while automation offers ways to resolve them.
-
Lipids that shift charge with pH can be chosen to fit the application and delivery route. Varied pKa and biodegradability give developers room to match each therapeutic target.
-
Ionizable lipid selection ratios shape how well lipid nanoparticles deliver nucleic acids, and empirical testing shows that similar physical properties can still produce very different performance.
-
Achieving successful extrahepatic CAR T delivery with LNPs requires addressing the unique biological and technological barriers and designing targeting approaches that leverage innovative LNP design.
-
Discover how a platform approach to AAV manufacturing can reduce development time and cost, as well as how optimized processes enable reliable production and scalable implementation in bioreactors.
-
Targeted LNPs that bypass the liver and home to the spleen could reshape in vivo CAR T cell manufacturing. See the data behind the approach.
-
Non-PEG stabilizer lipids may offer a new path for LNP design. Combining strong colloidal performance with greater chemical flexibility helps address growing concerns around PEG-related immunogenicity.
-
Personalized cancer vaccines are advancing quickly, but effective delivery remains a major hurdle. Learn how mRNA and lipid nanoparticle design influence targeting, endosomal escape, and repeat dosing.
NEWS
- Cytiva And Asimov Collaborate On Next Generation Cell Line Design And Process Development
- Innovation And Automation Are Driving Forces Behind Next Generation Cell Therapy Manufacturing Platform From Cytiva
- Precision NanoSystems And Aurora Vaccines Join Forces To Accelerate The Development Of Vaccine Candidate For Hepatitis C Virus
- Precision NanoSystems And Replicate Bioscience In Licensing Deal To Scale Up Genomic Medicines
- Cytiva And Multiply Labs Collaborate To Automate Cell Therapy Manufacturing
- Cytiva And Brooks Life Sciences To Enhance Automation In Cold Chain Solutions
- G-CON Manufacturing And GE Healthcare Announce Collaboration To Advance Early-Stage Cell Therapy And Viral Vector Manufacturing
- Scaling Up Cell Therapy Manufacturing In Guangzhou
- GE Healthcare Life Sciences Opens Cell And Gene Therapy Asia Technology Center In Shanghai